INmune Bio, Inc. (INMB), a clinical-stage biotechnology company focused on immunotherapy treatments, announced Tuesday the expansion of its ongoing Phase I/II trial to include veterans with metastatic castration-resistant prostate cancer or mCRPC at the West Los Angeles Veterans Administration or VA Medical Center.
This move underscores the company's commitment to addressing the high burden of prostate cancer within the U.S. veteran population, with over 200,000 veterans currently living with the disease.
The trial will evaluate INKmune, a novel NK cell-targeted therapy that primes the patient's own natural killer or NK cells to attack tumor cells.
INKmune offers a promising new approach to cancer treatment by enhancing the immune system without the need for conditioning, pre-medication, or cytokine support.
The Phase II portion of the trial is designed to assess the safety, immune response, and anti-cancer effects of INKmune in veterans with advanced prostate cancer.
INKmune works by stimulating NK cells to target cancer cells more effectively, specifically in prostate cancer, where NK cells are known to be abundant.
This treatment, administered in an outpatient setting with minimal side effects, offers a non-invasive alternative to traditional cancer therapies.
INmune Bio's trial expansion comes in response to growing legislative support for veterans' prostate cancer care, including the Cleland-Dole Act of 2022, which prioritizes clinical trials and advancements in prostate cancer treatments within the VA Health Care System.
The company aims to determine the optimal dose of INKmune for future clinical trials and to evaluate its potential as a first-line immunotherapy for prostate cancer.
The ongoing trial will also monitor immune responses, including the number of tumor-killing NK cells and changes in prostate-specific antigen or PSA levels.
This strategic expansion aligns with INmune Bio's mission to develop innovative immune therapies for cancer, leveraging its proprietary platforms to target and modulate the body's innate immune system.
Currently, INMB is trading at $7.75 down by 2.02%.
For comments and feedback: editorial@rttnews.com